Lialda Shire plc - Treatment for Ulcerative Colitis

Lialda is a once-daily oral formulation of mesalamine indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.

Posted: January 2007

Related Articles:

Lialda (mesalamine) FDA Approval History

View comments

Hide
(web2)